Serpentide
Serpentide developed a long-acting peptide therapeutics platform - SHIELD, which is versatile and scalable with broad applications beyond GLP1. Serpentide lead program - monthly administered GLP1 is partnering with Novo Nordisk.
)
January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)